Apo-Go

Apo-Go is a medication containing apomorphine hydrochloride hemihydrate, used for subcutaneous administration. It is primarily indicated for the treatment of Parkinson's disease symptoms, offering relief and improved mobility. This medication is manufactured by Stada Arzneimittel AG and is available in the EU market.

Apo-Go is commonly used to manage symptoms of Parkinson's disease, particularly motor fluctuations. It works by stimulating dopamine receptors in the brain, which can help alleviate stiffness, tremors, and other movement-related issues. Patients often use Apo-Go to improve their ability to perform daily activities and maintain mobility.

When administered subcutaneously, Apo-Go may cause effects such as nausea, dizziness, or drowsiness. Some users report improved mobility and reduced stiffness within a short period after administration. It is important to monitor for any adverse reactions and consult a healthcare provider if severe side effects occur.

Apo-Go should be handled with care, ensuring proper storage and administration techniques. It is crucial to follow the prescribed guidelines for subcutaneous use to minimize the risk of infection or irritation at the injection site. Patients with a history of severe nausea or hypotension should use this medication with caution.

Apo-Go may interact with other medications, particularly those that affect dopamine levels or blood pressure. Alcohol and certain antidepressants can also influence its effects. It is advisable to discuss all current medications with a healthcare provider to avoid potential interactions.